Condition
AK112
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (2)
Trial Status
Not Yet Recruiting3
Clinical Trials (3)
Showing 3 of 3 trials
NCT07162714Phase 2Not Yet Recruiting
SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer
NCT07086326Phase 2Not Yet Recruiting
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
NCT06766591Not ApplicableNot Yet Recruiting
Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs
Showing all 3 trials